Effects of silencing H-ras gene by RNA interference on cetuximab-sensitivity of cetuximab-resistant human nasopharyngeal carcinoma cells.
- Author:
Qiang ZUO
1
;
Rong-Cheng LUO
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal; pharmacology; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; pharmacology; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Nasopharyngeal Neoplasms; genetics; metabolism; pathology; Plasmids; Proto-Oncogene Proteins p21(ras); metabolism; RNA Interference; RNA, Small Interfering; genetics; Transfection
- From: Chinese Journal of Oncology 2011;33(8):574-578
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the changes of the sensitivity of cetuximab-resistant human nasopharyngeal carcinoma (hNPC) cells 5-8F/Erbitux to cetuximab by silencing H-ras gene with RNA interference (RNAi).
METHODSThe 5-8F/Erbitux cells were induced by stepwise exposure to increasing doses of cetuximab. Western blot was conducted to detect the protein levels of H-ras and K-ras. Real-time PCR was employed to detect the expression of H-ras and K-ras. H-ras-shRNA plasmids (shRNA vector carrying the H-ras gene) were constructed and transferred into 5-8F/Erbitux cells. The gene and protein expression levels of H-ras and the changes of the sensitivity of 5-8F/Erbitux cells to cetuximab after transfection were measured, respectively.
RESULTSAfter treatment with cetuximab for 3 and 5 days, the resistance index (RI) of the 5-8F/Erbitux cells was 1.2 and 1.1, and the protein levels of H-ras and K-ras in 5-8F/Erbitux cells were 0.798 +/- 0.019 and 0.190 +/- 0.011, respectively, significantly higher than that in the 5-8F cells (P<0.001). The gene expressions of H-ras and K-ras in 5-8F/Erbitux cells were 1.260 +/- 0.114 and 0.850 +/- 0.006, respectively. Compared with 5-8F cells, the former was higher (P = 0.016) and the latter was lower (P = 0.000). After transfection with H-ras-shRNA plasmid, the 5-8F/Erbitux cells showed reduced levels of H-ras gene and protein, and the cell apoptosis and inhibition rates increased significantly (P<0.001).
CONCLUSIONSH-ras siRNA can reverse cetuximab-resistance of 5-8F/Erbitux cells through down-regulation of H-ras gene expression, indicating that the generation of cetuximab-resistance in 5-8F/Erbitux cells is associated with amplification and overexpression of the H-ras gene.